Our Take
The delay signals regulatory scrutiny on delivery method changes, even for approved drugs switching from IV to subcutaneous.
Why it matters
Subcutaneous formulations reduce clinic visits and costs for Alzheimer's patients, making treatment more accessible. The delay affects competitive positioning against emerging Alzheimer's therapies.
Do this week
Neurology practices: review IV Leqembi capacity planning through Q3 since subcutaneous rollout is now delayed until late August.
FDA pushes Leqembi decision to late August
The FDA delayed approval of subcutaneous Leqembi from its original timeline of later this month to August 24, Biogen and Eisai announced. The agency requested additional information from the companies, though the specific details of the request were not disclosed in the public statement.
Leqembi (lecanemab) already has FDA approval for intravenous administration as an Alzheimer's treatment. The subcutaneous version would allow patients to self-administer the drug at home rather than requiring regular clinic visits for IV infusions.
Delivery method changes face regulatory barriers
The delay highlights how even approved drugs face scrutiny when changing delivery mechanisms. Subcutaneous formulations typically require demonstrating bioequivalence to the IV version, plus safety data on the new injection method.
For Alzheimer's patients, the stakes are high. IV Leqembi requires bi-weekly clinic visits, creating logistical and cost barriers. A subcutaneous option would reduce healthcare system burden while improving patient access, particularly in underserved areas with limited infusion capacity.
The timing also affects market dynamics. Other Alzheimer's drug developers are watching regulatory requirements for delivery method switches, as subcutaneous options become table stakes for patient convenience.
Plan for extended IV-only period
Neurology practices should maintain current IV infusion scheduling through August rather than reducing capacity in anticipation of subcutaneous availability. The two-month delay affects patient onboarding timelines and clinic resource allocation.
Practices considering Leqembi adoption should factor the extended IV-only period into cost-benefit analyses. Reimbursement patterns may also shift once subcutaneous options become available, affecting current revenue projections for infusion services.